0001628280-25-047538
SEC filingMembership growth of 25.9% and MBR improvement to 87.2% drove revenue up 43.5% YoY, with net income positive at $3.7M.
For the three months ended September 30, 2025, Alignment Healthcare reported total revenues of $993.7 million, a 43.5% increase from $692.4 million in the same period of 2024. The growth was primarily driven by a 25.9% increase in health plan membership to 229,600 and higher revenue per member per month due to increased CMS benchmark rates and Part D revenue changes from the Inflation Reduction Act. Medical expenses rose 41.5% to $868.0 million, but the medical benefits ratio (MBR) improved to 87.2% from 88.4% in the prior year, reflecting a favorable mix shift toward returning members. Income from operations was $7.7 million, compared to a loss of $19.5 million in Q3 2024, representing a 139.3% improvement. Net income reached $3.7 million, reversing a net loss of $26.4 million. Adjusted EBITDA, a non-GAAP measure, increased to $32.4 million from $5.9 million.
The company operates as a single reportable segment within the Medicare Advantage market. No segment-level breakdowns were provided. The MD&A focuses on aggregate metrics such as health plan membership, MBR, and adjusted gross profit to evaluate performance.
The MD&A does not provide explicit forward guidance. Management emphasizes continued investment in the AVA platform, new market expansion, and strategic acquisitions. The company believes its liquid assets of $644.1 million in cash and short-term investments will be sufficient for at least the next 12 months. The discontinuation of the ACO REACH model by year-end 2025 is noted as a strategic shift. No specific revenue or margin targets are given.
As of September 30, 2025, Alignment Healthcare holds $618.1M in cash and cash equivalents, a significant increase from $432.9M at December 31, 2024. Current investments (U.S. Treasury bills) add $26.0M. Total assets stand at $1.10B, largely driven by receivables ($219.8M) and goodwill/intangibles ($36.6M). Liabilities include medical expenses payable of $528.8M and long-term debt of $322.7M (net of issuance costs), representing the 4.25% convertible senior notes due 2029. Shareholders' equity is $161.9M, recovering from negative retained earnings trend; accumulated deficit narrows to $998.0M.
The Notes section does not disclose any purchase commitments, supply agreements, or capacity reservations. Commitments and Contingencies (Note 12) covers only legal proceedings and a risk adjustment data validation audit (RADV) for payment year 2019, with no estimated liability accrued beyond $0.9M for a class action settlement.
No share buyback programs, dividends, or new debt issuance are reported in the current period. The company repaid its Oxford term loan ($215M) in November 2024 using proceeds from the convertible notes. Capital expenditures are not separately disclosed in the notes; the cash flow statement (outside notes) shows $21.8M in acquisitions for the nine months.
Alignment Healthcare operates as a single reportable segment: providing healthcare services to seniors. The CODM evaluates performance using consolidated net income. All assets and operations are within the United States, with Medicare Advantage plans in California, North Carolina, Nevada, Arizona, and Texas. No further geographic or product-level disaggregation is provided.
Overall, the balance sheet reflects strong cash liquidity relative to debt, but the lack of purchase commitments or capital allocation details limits forward-looking insight from the notes alone.
Alignment Healthcare reported a dramatic improvement in operating cash flow (CFO) for the nine months ended September 30, 2025, reaching $190.3 million compared to $43.5 million in the prior year period. This increase was primarily driven by a $107 million swing in net income (from a loss of $97 million to a profit of $10 million) and non-cash adjustments like equity-based compensation and depreciation, combined with a $147 million increase in medical expenses payable.
Capital expenditures (capex) totaled $21.8 million, down from $32.1 million in 2024, indicating reduced investment intensity. CFO easily covered capex, resulting in significant free cash flow generation, though the company does not explicitly report free cash flow. Investing activities also included net maturities of investments and proceeds from a business sale, leading to a total investing cash outflow of $7.8 million.
Financing activities provided a modest $2.7 million, primarily from stock option exercises, with no debt issuance or share repurchases. The company ended the period with $620.2 million in cash and cash equivalents, up from $342.7 million at September 30, 2024.
Overall, the cash flow statement reflects a strong operational turnaround, with CFO more than quadrupling and ample liquidity for future investments or capital returns.